NTRK gene fusion overexpression represents a rare but important genetic change found in various types of cancer, where pieces of chromosomes break apart and join together in unusual ways, creating abnormal proteins that drive tumor growth across many different tissues in both adults and children.
Understanding NTRK Gene Fusions in Cancer
The NTRK genes, which include NTRK1, NTRK2, and NTRK3, normally play important roles in the development and functioning of the nervous system. These genes provide instructions for making proteins called TRK receptors, specifically TRKA, TRKB, and TRKC. In healthy bodies, these receptors help nerve cells develop, survive, and communicate with each other. They are activated when specific molecules called neurotrophins bind to them, triggering signals that support normal cell function.[1]
However, when something goes wrong during cell division, parts of chromosomes can break off and reconnect in the wrong places. When this happens to an NTRK gene, it can fuse with a completely different gene, creating what scientists call an NTRK gene fusion. This fusion typically involves the part of the NTRK gene that contains the kinase domain, which is responsible for sending growth signals, joining together with the beginning portion of an unrelated gene. The result is a hybrid or chimeric gene that produces an abnormal fusion protein.[2]
The fusion protein created by this genetic rearrangement is fundamentally different from normal TRK proteins. Unlike healthy TRK receptors that only become active when the right signal molecule attaches to them, these fusion proteins are constantly switched on without needing any signal. This means they continuously send growth messages to the cell, even when the cell should not be growing. This uncontrolled signaling can transform normal cells into cancer cells, making NTRK gene fusions important drivers of cancer development.[3]
Epidemiology: How Common Are NTRK Fusions?
NTRK gene fusions are considered rare genetic alterations when looking at all cancers together. In the general population of solid tumors, the prevalence of NTRK gene fusions is under one percent. Research examining more than 13,000 tumor samples found NTRK fusions in approximately 0.31% of adult cancers and 0.34% of pediatric tumors. This means that for every 1,000 cancer cases, only about three people would have an NTRK fusion.[1][12]
However, the story becomes more interesting when we look at specific cancer types. While NTRK fusions are rare overall, they are highly concentrated in certain rare tumor types. In some cancers, NTRK fusions are found in more than 80 to 90 percent of cases. These include infantile fibrosarcoma, a soft tissue cancer affecting young children; secretory breast carcinoma, an uncommon breast cancer subtype; and mammary analog secretory carcinoma of the salivary glands. In these particular cancers, finding an NTRK fusion is almost expected rather than surprising.[1][3]
NTRK fusions also appear at lower frequencies across many common cancer types. They have been identified in lung cancer, particularly non-small cell lung cancer where they occur in approximately 0.1 to 0.2 percent of cases. They can be found in colorectal cancer, sarcomas, thyroid cancers, and various other solid tumors affecting both adults and children. Interestingly, within colorectal cancers that have a specific characteristic called microsatellite instability along with normal KRAS, NRAS, and BRAF genes, the prevalence of NTRK fusions can be much higher, ranging from five to 44 percent.[5][11]
Each year, approximately 5,000 patients worldwide receive a diagnosis of NTRK fusion-positive cancer. The fusions occur across a wide range of tumor types, affecting people of all ages from infants to elderly adults. NTRK gene fusions do not show strong patterns related to gender, ethnicity, or geographic location, though certain rare cancers where they are common may have their own demographic patterns.[12]
Causes: Why Do NTRK Fusions Happen?
NTRK gene fusions occur through errors in the normal process of DNA repair. Our chromosomes, which contain all our genetic information, can break for various reasons during cell division or when cells are exposed to certain stresses. Normally, cells have sophisticated systems to detect these breaks and repair them accurately. However, sometimes the repair process makes mistakes. When two different chromosomes break around the same time, pieces can be accidentally joined together in the wrong way.[13]
The fusion happens through several possible mechanisms. An intrachromosomal rearrangement occurs when two breaks happen on the same chromosome, and the pieces reconnect incorrectly. An interchromosomal rearrangement happens when breaks on two different chromosomes lead to pieces being exchanged between them. There can also be deletions, where a piece of chromosome is lost, bringing genes that were previously far apart close together, or inversions, where a segment of chromosome flips around backward.[2]
What makes NTRK fusions particularly problematic is the structure of the resulting fusion gene. The fusion typically preserves the kinase domain from the NTRK gene, which is the part that sends growth signals, while the partner gene contributes portions that allow the fusion protein to be produced constantly or to be present in cells where it would not normally be found. The first NTRK gene fusion was identified back in 1982 in a colorectal cancer cell line, where researchers discovered an unusual rearrangement at a specific location on chromosome one.[4][14]
It is important to understand that these genetic changes happen by chance during a person’s lifetime. They are not caused by lifestyle choices, environmental exposures, or inherited from parents. The fusion occurs in a single cell or small group of cells, and because the fusion protein promotes uncontrolled growth, these cells multiply more rapidly than normal cells, eventually forming a tumor.[10]
Risk Factors: Who Is More Likely to Have NTRK Fusion Cancers?
Unlike some cancers where clear risk factors such as smoking, diet, or family history play major roles, NTRK fusion-positive cancers do not have well-defined risk factors that make certain people more likely to develop these fusions. The occurrence of the fusion appears to be largely random, happening through chance errors during cell division rather than being triggered by specific environmental or lifestyle factors.[1]
However, certain patterns have been observed. NTRK fusions are found across all age groups, affecting both pediatric and adult patients. Some of the cancers where NTRK fusions are most common occur primarily in children. For example, infantile fibrosarcoma, which has a very high rate of NTRK fusions, typically affects babies and young children. Other cancer types with high NTRK fusion rates, such as secretory breast carcinoma, can occur in adults at various ages.[3]
The type of cancer a person has can influence the likelihood of finding an NTRK fusion. While the fusion is rare in common cancers overall, certain rare cancer subtypes show much higher rates. Patients diagnosed with rare tumors, particularly those that are difficult to classify or have unusual features, may be more likely to have NTRK fusions. Additionally, in colorectal cancer, tumors that show microsatellite instability and lack mutations in other common driver genes like KRAS, NRAS, and BRAF have higher rates of NTRK fusions.[5]
Because NTRK fusions can occur in so many different cancer types, the actual risk factors are more related to the underlying cancer type itself rather than to the fusion. For instance, risk factors for developing lung cancer in general, such as smoking, would apply to someone who happens to develop lung cancer with an NTRK fusion. The fusion itself is a random event within the cancer rather than something that increases cancer risk.[11]
Symptoms: How NTRK Fusion Cancers Affect Patients
The symptoms experienced by patients with NTRK fusion-positive cancers are not specific to the genetic fusion itself but rather reflect the type and location of the cancer. Because NTRK fusions can occur in tumors throughout the body, the symptoms vary widely depending on which organ or tissue is affected. A child with infantile fibrosarcoma might have a visible lump or mass in an arm or leg, while an adult with lung cancer harboring an NTRK fusion might experience coughing, shortness of breath, or chest pain.[12]
Research has shown that NTRK fusion-positive tumors may have enhanced abilities to migrate and invade surrounding tissues. This means these cancers can be particularly aggressive, spreading to nearby tissues or distant parts of the body more readily than some other cancers. Patients may notice their tumors growing quickly or spreading to multiple sites. Clinical observations have noted that NTRK fusions are associated with increased tumor invasiveness and aggressiveness in some cases.[2][9]
The symptoms will typically align with the specific cancer type. For colorectal cancer with an NTRK fusion, symptoms might include changes in bowel habits, rectal bleeding, abdominal pain, or unexplained weight loss. For thyroid cancer with an NTRK fusion, patients might notice a lump in the neck, difficulty swallowing, or voice changes. Sarcomas can present as growing lumps anywhere in the body, sometimes causing pain or limiting movement if they press on nerves or interfere with joint function.[10]
One particularly interesting clinical observation involves the behavior of some NTRK fusion cancers. In at least one documented case of metastatic triple-negative breast cancer with an NTRK fusion, the disease showed a surprisingly slow growth pattern over several years, despite being an aggressive cancer type. The patient had widespread disease in the lungs but experienced a relatively stable course before targeted treatment. This suggests that NTRK fusion cancers may sometimes behave differently from what would be expected based on their cancer type alone.[4][14]
Prevention: Can NTRK Fusion Cancers Be Prevented?
Because NTRK gene fusions occur through random errors in DNA repair during cell division, there are no known ways to prevent these fusions from happening. The fusions are not caused by lifestyle factors, environmental exposures, or inherited genetic predispositions that can be modified or avoided. This means that traditional cancer prevention strategies, while important for overall cancer risk reduction, do not specifically target NTRK fusion development.[1]
However, prevention in the context of NTRK fusion cancers takes on a different meaning. The focus shifts from preventing the fusion itself to preventing poor outcomes through early detection and appropriate treatment. Regular screening for cancers that commonly harbor NTRK fusions, when screening is available for those cancer types, remains important. For example, regular colonoscopy screening for colorectal cancer or mammography for breast cancer could potentially detect these cancers earlier, when they may be more treatable.[5]
The most important preventive measure is ensuring that patients with cancer receive comprehensive molecular testing that can identify NTRK fusions when they are present. Early identification of the fusion allows doctors to select the most appropriate targeted therapy, which can lead to better outcomes. Healthcare professionals recommend that patients with certain cancer types, particularly rare tumors or cancers that lack other driver mutations, should undergo testing for NTRK fusions.[3][6]
For patients already diagnosed with cancer, preventing disease progression becomes the goal. This involves adhering to treatment plans, attending regular follow-up appointments, and reporting new symptoms promptly. For those receiving targeted therapy for NTRK fusion-positive cancer, taking medications as prescribed and monitoring for side effects helps prevent treatment interruptions that could allow the cancer to progress.[8]
Pathophysiology: How NTRK Fusions Drive Cancer
To understand how NTRK fusions cause cancer, it helps to first understand how normal TRK receptors work. In healthy cells, TRK proteins sit on the cell surface with part of them outside the cell and part inside. When the right molecule, called a neurotrophin, binds to the outside portion, the receptor changes shape. This activates the inside portion, which then sends signals into the cell. These signals tell the cell to grow, divide, or survive. The system is tightly controlled, with signals only being sent when appropriate.[3][10]
NTRK fusion proteins break this careful control system. When the NTRK gene fuses with another gene, the resulting fusion protein is structurally different from the normal receptor. Most importantly, the fusion protein loses the regulatory portions that keep it turned off when signals are not needed. The kinase domain, which is the part that sends growth signals, remains intact and becomes constitutively active. This means it is constantly switched on and continuously sending growth and survival signals into the cell, regardless of whether the cell actually needs to grow.[2][9]
The constantly active kinase triggers multiple cellular signaling pathways that promote cancer development. These include the MAPK/ERK pathway and the PI3K/AKT pathway, both of which regulate cell growth, division, and survival. When these pathways are continuously activated by the fusion protein, cells receive relentless instructions to multiply and avoid normal cell death processes. Over time, this leads to the accumulation of cancerous cells that form a tumor.[9]
Research has shown that NTRK fusions can promote cancer spread through a process called epithelial-mesenchymal transition, or EMT. In this process, cells that would normally stay in one place become more mobile and invasive. The cells change their characteristics, losing connections with neighboring cells and gaining the ability to move through tissues and enter blood vessels. This helps explain why NTRK fusion-positive tumors can be particularly aggressive and prone to spreading to distant sites in the body.[2][9]
The fusion proteins also interact with other cellular molecules to enhance their cancer-causing effects. Studies have identified relationships between NTRK fusions and proteins called ECM1 and NOVA1, which appear to be involved in the ability of fusion-positive tumors to migrate and invade surrounding tissues. These complex molecular interactions demonstrate that the fusion protein does not work alone but rather disrupts multiple interconnected cellular processes.[2][9]
Importantly, NTRK fusions act as independent oncogenic drivers. This means they are sufficient on their own to transform normal cells into cancer cells and are typically found without other major driver mutations such as mutations in KRAS, EGFR, or ALK. In the world of cancer genetics, NTRK fusions are considered mutually exclusive with these other common drivers. When a cancer has an NTRK fusion, it usually does not have these other mutations, and vice versa.[2][9]
